Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2019

Open Access 01-12-2019 | Breast Cancer | Review

Genetic and molecular biology of breast cancer among Iranian patients

Author: Meysam Moghbeli

Published in: Journal of Translational Medicine | Issue 1/2019

Login to get access

Abstract

Abstract

Background, Breast cancer (BC) is one of the leading causes of cancer related deaths in Iran. This high ratio of mortality had a rising trend during the recent years which is probably associated with late diagnosis.

Main body

Therefore it is critical to define a unique panel of genetic markers for the early detection among our population. In present review we summarized all of the reported significant genetic markers among Iranian BC patients for the first time, which are categorized based on their cellular functions.

Conclusions

This review paves the way of introducing a unique ethnic specific panel of diagnostic markers among Iranian BC patients. Indeed, this review can also clarify the genetic and molecular bases of BC progression among Iranians.
Literature
1.
Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757–61.PubMedCrossRef
2.
Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev. 2016;17(S3):47–52.PubMedCrossRef
3.
Mousavi SM, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383–91.PubMedCrossRef
4.
Sharifian A, et al. Burden of Breast Cancer in Iranian Women is Increasing. Asian Pac J Cancer Prev. 2015;16(12):5049–52.PubMedCrossRef
5.
Mahdavifar N, et al. Spatial analysis of breast cancer incidence in Iran. Asian Pac J Cancer Prev. 2016;17(S3):59–64.PubMedCrossRef
6.
Afsharfard A, et al. Trends in epidemiology, clinical and histopathological characteristics of breast cancer in Iran: results of a 17 year study. Asian Pac J Cancer Prev. 2013;14(11):6905–11.PubMedCrossRef
7.
Abdulrahman GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol. 2012;2012:915610.PubMedCrossRef
8.
9.
Iqbal J, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.PubMedCrossRef
10.
Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10(7):705–13.PubMedCrossRef
11.
Xu X, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22(1):37–43.PubMedCrossRef
12.
Sidransky D, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984–6.PubMed
13.
14.
15.
16.
17.
Danesh H, et al. Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene. 2018;647:73–8.PubMedCrossRef
18.
Zhang Y, et al. Estrogen receptor alpha signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem. 2012;287(49):41514–22.PubMedPubMedCentralCrossRef
19.
Heydari N, et al. Overexpression of serum MicroRNA-140-3p in premenopausal women with newly diagnosed breast cancer. Gene. 2018;655:25–9.PubMedCrossRef
20.
Parchami Barjui S, et al. Study of correlation between genetic variants in three microRNA genes (hsa-miR-146a, hsa-miR-502 binding site, hsa-miR-27a) and breast cancer risk. Curr Res Transl Med. 2017;65(4):141–7.PubMedCrossRef
21.
Omrani M, et al. Hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8(2):259–67.PubMedCrossRef
22.
Landi D, et al. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol. 2008;27(1):35–43.PubMedCrossRef
23.
Hashemi M, et al. miR-608 rs4919510 C > G polymorphism decreased the risk of breast cancer in an Iranian subpopulation. Exp Oncol. 2016;38(1):57–9.PubMedCrossRef
24.
Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68(19):8164–72.PubMedCrossRef
25.
Qi L, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163.PubMedPubMedCentralCrossRef
26.
Savad S, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev. 2012;13(3):873–7.PubMedCrossRef
27.
Zenz T, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801–8.PubMedCrossRef
28.
Mansoori B, et al. Micro RNA 34a and Let-7a expression in human breast cancers is associated with apoptotic expression genes. Asian Pac J Cancer Prev. 2016;17(4):1887–90.PubMedCrossRef
29.
Saberi A, et al. MiR-328 may be considered as an oncogene in human invasive breast carcinoma. Iran Red Crescent Med J. 2016;18(11):e42360.PubMedPubMedCentral
30.
Damavandi Z, et al. Aberrant expression of breast development-related microRNAs, miR-22, miR-132, and miR-212, breast tumor tissues. J Breast Cancer. 2016;19(2):148–55.PubMedPubMedCentralCrossRef
31.
Ma XP, et al. Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. PLoS ONE. 2013;8(11):e79584.PubMedPubMedCentralCrossRef
32.
Nejati-Azar A, Alivand MR. miRNA 196a2(rs11614913) & 146a(rs2910164) polymorphisms & breast cancer risk for women in an Iranian population. Per Med. 2018;15(4):279–89.PubMedCrossRef
33.
Cai Y, He J, Zhang D. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco Targets Ther. 2015;8:2657–64.PubMedPubMedCentral
34.
Ling H, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23(9):1446–61.PubMedPubMedCentralCrossRef
35.
36.
37.
Hassanzarei S, et al. Genetic polymorphisms of HOTAIR gene are associated with the risk of breast cancer in a sample of southeast Iranian population. Tumour Biol. 2017;39(10):1010428317727539.PubMedCrossRef
38.
Zhouravleva G, et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 1995;14(16):4065–72.PubMedPubMedCentralCrossRef
39.
Hoshino S, et al. Novel function of the eukaryotic polypeptide-chain releasing factor 3 (eRF3/GSPT) in the mRNA degradation pathway. Biochemistry (Mosc). 1999;64(12):1367–72.
40.
Hansen LL, Jakobsen CG, Justesen J. Assignment of the human peptide chain release factor 3 (GSPT2) to Xp11.23– > p11.21 and of the distal marker DXS1039 by radiation hybrid mapping. Cytogenet Cell Genet. 1999;86(3–4):250–1.PubMedCrossRef
41.
Ozawa K, et al. Mapping of the human GSPT1 gene, a human homolog of the yeast GST1 gene, to chromosomal band 16p131. Somat Cell Mol Genet. 1992;18(2):189–94.PubMedCrossRef
42.
Miri M, et al. GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility. Med Oncol. 2012;29(3):1581–5.PubMedCrossRef
43.
44.
Ueland PM, et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001;22(4):195–201.PubMedCrossRef
45.
46.
Rezaei H, Rassi H, Mansur FN. Investigation of Methylenetetrahydrofolate reductase C677T polymorphism and human papilloma virus genotypes in Iranian breast cancer. Monoclon Antib Immunodiagn Immunother. 2017;36(3):124–8.PubMedCrossRef
47.
Johansson HJ, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:2175.PubMedCrossRef
48.
Jahangiri R, et al. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients. Gene. 2018;685:24–31.PubMedCrossRef
49.
Eftekhar E, et al. The study of DNA methyltransferase-3B promoter variant genotype among iranian sporadic breast cancer patients. Iran J Med Sci. 2014;39(3):268–74.PubMedPubMedCentral
50.
Ghavami S, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009;46(8):497–510.PubMedCrossRef
51.
Hashemi M, et al. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6 N ins/del promoter polymorphism (rs3834129) in breast cancer. Gene. 2012;505(1):176–9.PubMedCrossRef
52.
Aghababazadeh M, et al. Downregulation of Caspase 8 in a group of Iranian breast cancer patients—a pilot study. J Egypt Natl Canc Inst. 2017;29(4):191–5.PubMedCrossRef
53.
Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003;21(3):321–6.PubMedCrossRef
54.
Eskandari-Nasab E, et al. Effect of TP53 16-bp and beta-TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer. Gene. 2015;568(2):181–5.PubMedCrossRef
55.
Payandeh M, et al. Expression of p53 breast cancer in kurdish women in the West of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev. 2016;17(3):1261–4.PubMedCrossRef
56.
57.
58.
Rostamizadeh L, et al. Bcl-2 gene expression in human breast cancers in iran. Asian Pac J Cancer Prev. 2013;14(7):4209–14.PubMedCrossRef
59.
Freeman DJ, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117–30.PubMedCrossRef
60.
Li AG, et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575–87.PubMedCrossRef
61.
Golmohammadi R, et al. Prognostic role of PTEN gene expression in breast cancer patients from north-east Iran. Asian Pac J Cancer Prev. 2016;17(9):4527–31.PubMed
62.
Sadeq V, Isar N, Manoochehr T. Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med Oncol. 2011;28(2):420–3.PubMedCrossRef
63.
Yari K, Payandeh M, Rahimi Z. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran. Tumour Biol. 2016;37(6):8145–52.PubMedCrossRef
64.
Ghaffari K, et al. BIRC5 genomic copy number variation in early-onset breast cancer. Iran Biomed J. 2016;20(4):241–5.PubMedPubMedCentral
65.
Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264(1):42–55.PubMedCrossRef
66.
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6456):704–7.CrossRefPubMed
67.
Nielsen NH, et al. Methylation of the p16(Ink4a) tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett. 2001;163(1):59–69.PubMedCrossRef
68.
Kannan K, et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA. 2003;100(3):1221–5.PubMedCrossRefPubMedCentral
69.
Malumbres M, et al. Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol. 2000;20(8):2915–25.PubMedPubMedCentralCrossRef
70.
Vallian S, et al. Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol. 2009;135(8):991–6.PubMedCrossRef
71.
Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst. 2000;92(10):795–802.PubMedCrossRef
72.
Salimi M, Mozdarani H, Majidzadeh K. Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol. 2012;29(3):1502–9.PubMedCrossRef
73.
Mehdipour P, et al. Importance of ATM gene as a susceptible trait: predisposition role of D1853 N polymorphism in breast cancer. Med Oncol. 2011;28(3):733–7.PubMedCrossRef
74.
Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401(6750):297–300.PubMedCrossRef
75.
Amininia S, et al. Association between CCNE1 polymorphisms and the risk of breast cancer in a sample of southeast Iranian population. Med Oncol. 2014;31(10):189.PubMedCrossRef
76.
Yoshihara T, Collado D, Hamaguchi M. Cyclin D1 down-regulation is essential for DBC2′s tumor suppressor function. Biochem Biophys Res Commun. 2007;358(4):1076–9.PubMedPubMedCentralCrossRef
77.
Siripurapu V, et al. DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J Mol Biol. 2005;346(1):83–9.PubMedCrossRef
78.
Hajikhan Mirzaei M, et al. Evaluation of Methylation Status in the 5′UTR Promoter Region of the DBC2 Gene as a Biomarker in Sporadic Breast Cancer. Cell J. 2012;14(1):19–24.PubMedPubMedCentral
79.
Golmohammadi R, et al. A single nucleotide polymorphism in codon F31I and V57I of the AURKA gene in invasive ductal breast carcinoma in Middle East. Medicine (Baltimore). 2017;96(37):e7933.CrossRef
80.
81.
Dai L, et al. XRCC1 gene polymorphisms and esophageal squamous cell carcinoma risk in Chinese population: a meta-analysis of case–control studies. Int J Cancer. 2009;125(5):1102–9.PubMedCrossRef
82.
Yu H, et al. Interaction between XRCC1 polymorphisms and intake of long-term stored rice in the risk of esophageal squamous cell carcinoma: a case-control study. Biomed Environ Sci. 2011;24(3):268–74.PubMed
83.
Jalali C, et al. Association of XRCC1 Trp194 allele with risk of breast cancer, and Ki67 protein status in breast tumor tissues. Saudi Med J. 2016;37(6):624–30.PubMedPubMedCentralCrossRef
84.
Liu L, et al. Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. Carcinogenesis. 2012;33(1):119–23.PubMedCrossRef
85.
Shen B, et al. Multiple but dissectible functions of FEN-1 nucleases in nucleic acid processing, genome stability and diseases. BioEssays. 2005;27(7):717–29.PubMedCrossRef
86.
87.
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.PubMedCrossRef
88.
Madjd Z, et al. Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. Asian Pac J Cancer Prev. 2014;15(4):1783–9.PubMedCrossRef
89.
Gatei M, et al. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res. 2000;60(12):3299–304.PubMed
90.
91.
Hallajian Z, Mahjoubi F, Nafissi N. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients. Breast Cancer. 2017;24(4):624–34.PubMedCrossRef
92.
93.
Paterson JW. BRCA1: a review of structure and putative functions. Dis Markers. 1998;13(4):261–74.PubMedCrossRef
94.
Darbeheshti F, et al. Comparison of BRCA1 expression between triple-negative and luminal breast tumors. Iran Biomed J. 2018;22(3):210–4.PubMedPubMedCentral
95.
Madjd Z, et al. BRCA1 protein expression level and CD44(+)phenotype in breast cancer patients. Cell J. 2011;13(3):155–62.PubMedPubMedCentral
96.
Rezaei M, et al. APOBEC3 deletion is associated with breast cancer risk in a sample of southeast Iranian population. Int J Mol Cell Med. 2015;4(2):103–8.PubMedPubMedCentral
97.
Hussain S, et al. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet. 2003;12(19):2503–10.PubMedCrossRef
98.
99.
100.
Vodenicharov MD, Wellinger RJ. The cell division cycle puts up with unprotected telomeres: cell cycle regulated telomere uncapping as a means to achieve telomere homeostasis. Cell Cycle. 2007;6(10):1161–7.PubMedCrossRef
101.
102.
Hashemi M, et al. Association between hTERT polymorphisms and the risk of breast cancer in a sample of Southeast Iranian population. BMC Res Notes. 2014;7:895.PubMedPubMedCentralCrossRef
103.
104.
Elliott RL, et al. Human leukocyte antigen G expression in breast cancer: role in immunosuppression. Cancer Biother Radiopharm. 2011;26(2):153–7.PubMedCrossRef
105.
Pistillo MP, et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol. 2000;61(4):397–407.PubMedCrossRef
106.
Salih HR, Nussler V. Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res. 2001;6(8):323–32.PubMed
107.
Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 2006;24(2):178–86.PubMedCrossRef
108.
Haghi M, et al. 14-bp insertion/deletion polymorphism of the HLA-G gene in breast cancer among women from north western Iran. Asian Pac J Cancer Prev. 2015;16(14):6155–8.PubMedCrossRef
109.
Mahmoodi M, et al. HLA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer. Pathol Oncol Res. 2012;18(1):49–55.PubMedCrossRef
110.
Ghaderi A, et al. HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res. 2001;7(1):39–41.PubMedCrossRef
111.
Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111(4):677–90 (quiz 691).PubMedCrossRef
112.
113.
Faghih Z, et al. Interleukin13 haplotypes and susceptibility of Iranian women to breast cancer. Mol Biol Rep. 2009;36(7):1923–8.PubMedCrossRef
114.
Owaki T, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol. 2005;175(4):2191–200.PubMedCrossRef
115.
Pflanz S, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 + T cells. Immunity. 2002;16(6):779–90.PubMedCrossRef
116.
Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–25.PubMedCrossRef
117.
Aggarwal S, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–4.PubMedCrossRef
118.
Zheng Y, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648–51.PubMedCrossRef
119.
Khodadadi A, et al. IL-23/IL-27 Ratio in Peripheral Blood of Patients with Breast Cancer. Iran J Med Sci. 2014;39(4):350–6.PubMedPubMedCentral
120.
Vahedi L, et al. Investigation of CCR120 marker expression using immunohistochemical method and its association with clinicopathologic properties in patients with breast cancer. Int J Hematol Oncol Stem Cell Res. 2018;12(2):103–10.PubMedPubMedCentral
121.
Yamashita U, Kuroda E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol. 2002;22(2):105–14.PubMedCrossRef
122.
Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759–67.PubMed
123.
Jafarzadeh A, et al. Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism. Tumour Biol. 2015;36(2):1163–71.PubMedCrossRef
124.
Dayer R, et al. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: a potent biomarker predicting lymph node metastasis. J Cancer Res Ther. 2018;14(2):345–50.PubMed
125.
Fontenot JD, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22(3):329–41.PubMedCrossRef
126.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61.PubMedCrossRef
127.
Jaberipour M, et al. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010;16(4):547–51.PubMedCrossRef
128.
Hamidinia M, et al. Concomitant Increase of OX40 and FOXP3 transcripts in peripheral blood of patients with breast cancer. Iran J Immunol. 2013;10(1):22–30.PubMed
129.
Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRef
130.
Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book. 2013;1:46–51.CrossRef
131.
Pierce BL, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437–44.PubMedPubMedCentralCrossRef
132.
Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;14(2):189–206.PubMedCrossRef
133.
Guo S, et al. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 2012;1825(2):207–22.PubMedPubMedCentral
134.
Rostami S, Kohan L, Mohammadianpanah M. The LEP G-2548A gene polymorphism is associated with age at menarche and breast cancer susceptibility. Gene. 2015;557(2):154–7.PubMedCrossRef
135.
Babaei Z, et al. Relationship of obesity with serum concentrations of leptin, CRP and IL-6 in breast cancer survivors. J Egypt Natl Canc Inst. 2015;27(4):223–9.PubMedCrossRef
136.
Mohammadzadeh G, et al. The relationship between -2548 G/A Leptin gene polymorphism and risk of breast cancer and serum leptin levels in Ahvazian women. Iran J Cancer Prev. 2015;8(2):100–8.PubMedPubMedCentral
137.
Basu B, et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells. J Biol Chem. 2010;285(35):27026–32.PubMedPubMedCentralCrossRef
138.
Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182–217.PubMedCrossRef
139.
Kirillova GP, et al. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J Neurosci Methods. 2008;174(2):272–80.PubMedPubMedCentralCrossRef
140.
Pornour M, et al. Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer. Asian Pac J Cancer Prev. 2014;15(23):10339–43.PubMedCrossRef
141.
Amani D, et al. Transforming growth factor beta1 (TGFbeta1) polymorphisms and breast cancer risk. Tumour Biol. 2014;35(5):4757–64.PubMedCrossRef
142.
Parvizi S, et al. Effects of two common promoter polymorphisms of transforming growth factor-beta1 on breast cancer risks in Ahvaz, west south of Iran. Iran J Cancer Prev. 2016;9(1):e5266.PubMedPubMedCentral
143.
Tabatabaeian H, Hojati Z. Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry. Gene. 2013;531(1):39–43.PubMedCrossRef
144.
Panahi M, et al. Expressional correlation of human epidermal growth factor receptor 2, estrogen/progesterone receptor and protein 53 in breast cancer. Asian Pac J Cancer Prev. 2013;14(6):3699–703.PubMedCrossRef
145.
Amirifard N, et al. Relationship between HER2 proto-oncogene status and prognostic factors of breast cancer in the west of Iran. Asian Pac J Cancer Prev. 2016;17(1):295–8.PubMedCrossRef
146.
Salimi Z, et al. rs11895168 C allele and the increased risk of breast cancer in Isfahan population. Breast. 2016;28:89–94.PubMedCrossRef
147.
Mansouri Bidkani M, et al. ErbB4 receptor polymorphism 2368A > C and risk of breast cancer. Breast. 2018;42:157–63.PubMedCrossRef
148.
Bagheri F, et al. Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3′-untranslated region of ErbB4 in breast cancer. Mol Med Rep. 2016;13(5):4494–8.PubMedCrossRef
149.
Normanno N, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.PubMedCrossRef
150.
151.
Wang L, et al. NGX6 gene inhibits cell proliferation and plays a negative role in EGFR pathway in nasopharyngeal carcinoma cells. J Cell Biochem. 2005;95(1):64–73.PubMedCrossRef
152.
Eskandari-Nasab E, et al. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep. 2012;39(12):10531–9.PubMedCrossRef
153.
Naik A, et al. Neuropilin-1 associated molecules in the blood distinguish poor prognosis breast cancer: a cross-sectional study. Sci Rep. 2017;7(1):3301.PubMedPubMedCentralCrossRef
154.
155.
Cleveland RJ, et al. IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis. 2006;27(4):758–65.PubMedCrossRef
156.
Javadi M, Hematti S, Tavassoli M. Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women. Med Oncol. 2012;29(2):516–20.PubMedCrossRef
157.
Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253(1):239–54.PubMedCrossRef
158.
Azizi Tabesh G, et al. The high frequency of PIK3CA mutations in iranian breast cancer patients. Cancer Invest. 2017;35(1):36–42.PubMedCrossRef
159.
Sanaei S, et al. KRAS gene polymorphisms and their impact on breast cancer risk in an Iranian population. Asian Pac J Cancer Prev. 2017;18(5):1301–5.PubMedPubMedCentral
160.
Nazouri AS, et al. High expression of sphingosine kinase 1 in estrogen and progesterone receptors-negative breast cancer. Iran J Pathol. 2017;12(3):218–24.PubMedPubMedCentral
161.
Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10(5):342–52.PubMedCrossRef
162.
163.
164.
Heshmatpour N, et al. Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk. Med Oncol. 2014;31(7):29.PubMedCrossRef
165.
Ghalaei A, et al. Overexpressed in colorectal carcinoma gene (OCC-1) upregulation and APPL2 gene downregulation in breast cancer specimens. Mol Biol Rep. 2018;45(6):1889–95.PubMedCrossRef
166.
Karami-Tehrani F, et al. Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors. Tumour Biol. 2016;37(7):8849–56.PubMedCrossRef
167.
Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res. 2003;5(1):8–15.PubMedCrossRef
168.
Nikseresht M, et al. Overexpression of the novel human gene, UBE2Q2, in breast cancer. Cancer Genet Cytogenet. 2010;197(2):101–6.PubMedCrossRef
169.
Vogl FD, et al. Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2004;13(9):1473–9.PubMed
170.
Hashemi M, et al. Association between polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer risk in a sample Iranian population. Biomark Med. 2012;6(6):797–803.PubMedCrossRef
171.
Sharif MR, et al. Association of GSTO1 A140D and GSTO2 N142D gene variations with breast cancer risk. Asian Pac J Cancer Prev. 2017;18(6):1723–7.PubMedPubMedCentral
172.
Petersen DD, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet. 1991;48(4):720–5.PubMedPubMedCentral
173.
Saadatian H, et al. Polymorphism of the cytochrome P-450 1A1 (A2455G) in women with breast cancer in Eastern Azerbaijan, Iran. Iran J Basic Med Sci. 2014;17(3):227–30.PubMedPubMedCentral
174.
Saghafi F, et al. CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomed Rep. 2018;9(5):446–52.PubMedPubMedCentral
175.
Darakhshan S, et al. Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev. 2013;14(11):6869–74.PubMedCrossRef
176.
Motamedi S, et al. Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev. 2012;13(12):6101–4.PubMedCrossRef
177.
Meiyanto E, Hermawan A, Anindyajati A. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 2012;13(2):427–36.PubMedCrossRef
178.
179.
Yazdi MF, et al. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6783–7.PubMedCrossRef
180.
Ciocca DR, et al. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst. 1993;85(19):1558–70.PubMedCrossRef
181.
Mehlen P, et al. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol. 1995;154(1):363–74.PubMed
182.
Calderwood SK, et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31(3):164–72.PubMedCrossRef
183.
Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012;5(1):7.PubMedPubMedCentralCrossRef
184.
Homaei-Shandiz F, et al. Anti-heat shock protein-27 antibody levels in women with breast cancer: association with disease complications and two-year disease-free survival. Asian Pac J Cancer Prev. 2016;17(10):4655–9.PubMedPubMedCentral
185.
Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014;10(10):1337–54.PubMedCrossRef
186.
Durmus S, Hendrikx JJ, Schinkel AH. Apical ABC transporters and cancer chemotherapeutic drug disposition. Adv Cancer Res. 2015;125:1–41.PubMedCrossRef
187.
Ghafouri H, et al. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer. Tumour Biol. 2016;37(6):7901–6.PubMedCrossRef
188.
Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3–4):643–71.PubMedCrossRef
189.
Estiar MA, et al. High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer. Clin Exp Med. 2017;17(4):547–53.PubMedCrossRef
190.
Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem. 2007;22(1):57–60.PubMedPubMedCentralCrossRef
191.
Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem. 1999;36(Pt 5):579–86.PubMedCrossRef
192.
Moazzezy N, et al. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev. 2014;15(4):1685–8.PubMedCrossRef
193.
Mansouri N, et al. Overexpression of the MUC1 gene in Iranian women with breast cancer micrometastasis. Asian Pac J Cancer Prev. 2016;17(S3):275–8.PubMedCrossRef
194.
Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6(8):622–34.PubMedCrossRef
195.
Tepass U, et al. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol. 2000;1(2):91–100.PubMedCrossRef
196.
Zarei F, et al. Higher risk of progressing breast cancer in Kurdish population associated to CDH1 -160 C/A polymorphism. EXCLI J. 2017;16:1198–205.PubMedPubMedCentral
197.
Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMedCrossRef
198.
Esmaeili R, et al. Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis. Cancer Cell Int. 2018;18:28.PubMedPubMedCentralCrossRef
199.
Maetzel D, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162–71.PubMedCrossRef
200.
Gottlinger HG, et al. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer. 1986;38(1):47–53.PubMedCrossRef
201.
202.
Sadeghi S, Hojati Z, Tabatabaeian H. Cooverexpression of EpCAM and c-myc genes in malignant breast tumours. J Genet. 2017;96(1):109–18.PubMedCrossRef
203.
Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389–96.PubMedCrossRef
204.
Taghizadeh-Kermani A, et al. The stromal overexpression of CD10 in invasive breast cancer and its association with clincophathologic factors. Iran J Cancer Prev. 2014;7(1):17–21.PubMedPubMedCentral
205.
206.
Williams TM, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004;279(49):51630–46.PubMedCrossRef
207.
Fard ZT, Nafisi N. The relationship between 6 polymorphisms of Caveolin-1 gene and the risk of breast cancer. Clin Breast Cancer. 2018;18(5):e893–8.PubMedCrossRef
208.
Mobasheri MB, Shirkoohi R, Modarressi MH. Synaptonemal complex protein 3 transcript analysis in breast cancer. Iran J Public Health. 2016;45(12):1618–24.PubMedPubMedCentral
209.
Malek-Hosseini Z, et al. Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size. Breast Cancer. 2017;24(6):742–7.PubMedCrossRef
210.
Rehman G, et al. Role of AMP-activated protein kinase in cancer therapy. Arch Pharm (Weinheim). 2014;347(7):457–68.CrossRef
211.
Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725–48.PubMedCrossRef
212.
213.
Karami-Tehrani F, et al. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43(6):470–5.PubMedCrossRef
214.
Fiscus RR, Murad F. cGMP-dependent protein kinase activation in intact tissues. Methods Enzymol. 1988;159:150–9.PubMedCrossRef
215.
Karami-Tehrani F, Fallahian F, Atri M. Expression of cGMP-dependent protein kinase, PKGIalpha, PKGIbeta, and PKGII in malignant and benign breast tumors. Tumour Biol. 2012;33(6):1927–32.PubMedCrossRef
216.
217.
Moghbeli M, et al. Role of Msi1 and MAML1 in regulation of notch signaling pathway in patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 2015;46(4):365–9.PubMedCrossRef
218.
219.
Moghbeli M, et al. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal. 2016;10(1):49–53.PubMedCrossRef
220.
Taghavi A, et al. Gene expression profiling of the 8q22-24 position in human breast cancer: TSPYL5, MTDH, ATAD2 and CCNE2 genes are implicated in oncogenesis, while WISP1 and EXT1 genes may predict a risk of metastasis. Oncol Lett. 2016;12(5):3845–55.PubMedPubMedCentralCrossRef
221.
222.
Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1(5):485–7.PubMedCrossRef
223.
Ginestier C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.PubMedPubMedCentralCrossRef
224.
Madjd Z, et al. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6):2973–8.PubMedCrossRef
225.
226.
Yu FL, Bender W. A proposed mechanism of tamoxifen in breast cancer prevention. Cancer Detect Prev. 2002;26(5):370–5.PubMedCrossRef
227.
Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.PubMedCrossRef
228.
Eccles MR, et al. PAX genes in development and disease: the role of PAX2 in urogenital tract development. Int J Dev Biol. 2002;46(4):535–44.PubMed
229.
Jahangiri R, et al. PAX2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients. Tissue Cell. 2018;52:135–42.PubMedCrossRef
230.
Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem. 2006;281(46):34725–9.PubMedCrossRef
231.
Qu X, et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.PubMedCrossRef
232.
Zhao W, et al. Cloning and expression pattern of the human NDRG3 gene. Biochim Biophys Acta. 2001;1519(1–2):134–8.PubMedCrossRef
233.
Estiar MA, et al. Clinical significance of NDRG3 in patients with breast cancer. Future Oncol. 2017;13(11):961–9.PubMedCrossRef
234.
Hosseini A, et al. Estrogen receptor alpha gene expression in breast cancer tissues from the Iranian population–a pilot study. Asian Pac J Cancer Prev. 2014;15(20):8789–91.PubMedCrossRef
235.
Abbasi S, et al. Association of estrogen receptor-alpha A908G (K303R) mutation with breast cancer risk. Int J Clin Exp Med. 2013;6(1):39–49.PubMed
236.
Farzaneh F, et al. Analysis of CYP17, CYP19 and CYP1A1 Gene polymorphisms in Iranian women with breast cancer. Asian Pac J Cancer Prev. 2016;17(S3):23–6.PubMedCrossRef
237.
Duncan LJ, Coldham NG, Reed MJ. The interaction of cytokines in regulating oestradiol 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol. 1994;49(1):63–8.PubMedCrossRef
238.
Newman SP, et al. Regulation of steroid sulphatase expression and activity in breast cancer. J Steroid Biochem Mol Biol. 2000;75(4–5):259–64.PubMedCrossRef
239.
Danforth DN, Sgagias MK. Tumour necrosis factor-alpha modulates oestradiol responsiveness of MCF-7 breast cancer cells in vitro. J Endocrinol. 1993;138(3):517–28.PubMedCrossRef
240.
Roodi N, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87(6):446–51.PubMedCrossRef
241.
Kamali-Sarvestani E, et al. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res. 2005;11(2):99–102.PubMedCrossRef
242.
Di C, et al. Basophil-associated OX40 ligand participates in the initiation of Th2 responses during airway inflammation. J Biol Chem. 2015;290(20):12523–36.PubMedPubMedCentralCrossRef
243.
Lee J, et al. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology. 2008;125(2):229–40.PubMedPubMedCentralCrossRef
244.
Ohshima Y, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159(8):3838–48.PubMed
245.
Vakil R, Mashayekhi F. OX40L gene polymorphism and breast cancer in Iranian population. Exp Oncol. 2018;40(2):132–5.CrossRef
246.
Crew KD. Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol. 2013;2013:483687.PubMedPubMedCentral
247.
Jurutka PW, et al. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2(2):203–16.PubMedCrossRef
248.
249.
Barsony J, Prufer K. Vitamin D receptor and retinoid X receptor interactions in motion. Vitam Horm. 2002;65:345–76.PubMedCrossRef
250.
Colagar AH, Firouzjah HM, Halalkhor S. Vitamin D Receptor Poly(A) Microsatellite Polymorphism and 25-Hydroxyvitamin D Serum Levels: association with Susceptibility to Breast Cancer. J Breast Cancer. 2015;18(2):119–25.PubMedPubMedCentralCrossRef
251.
Anderson MG, et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57(2):234–40.PubMedCrossRef
252.
Anderson PH, et al. Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase- polymerase chain reaction. J Mol Endocrinol. 2003;31(1):123–32.PubMedCrossRef
253.
Haussler MR, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77–98.PubMedCrossRef
254.
255.
Zhalehjoo N, Shakiba Y, Panjehpour M. Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues. Mol Med Rep. 2017;15(1):467–73.PubMedCrossRef
256.
Shahabi A, et al. Vitamin D receptor gene polymorphism: association with susceptibility to early-onset breast cancer in Iranian, BRCA1/2-mutation carrier and non-carrier patients. Pathol Oncol Res. 2018;24(3):601–7.PubMedCrossRef
257.
Shahbazi S, et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.PubMedCrossRef
258.
Reid AH, et al. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610–20.PubMedCrossRef
259.
Setiawan VW, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2007;16(11):2237–46.PubMedCrossRef
260.
Ebrahimi E, et al. CYP17 MspA1 gene polymorphism and breast cancer patients according to age of onset in cancer institute of Iran. Iran J Public Health. 2017;46(4):537–44.PubMedPubMedCentral
261.
Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1.PubMed
262.
Salmaninejad A, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–40.PubMedCrossRef
263.
264.
Lim SK, et al. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor alpha function in breast cancer via the Wnt pathway. FASEB J. 2011;25(9):3004–18.PubMedCrossRef
265.
Nourashrafeddin S, et al. Expression analysis of PAWP during mouse embryonic stem cell-based spermatogenesis in vitro. Vitro Cell Dev Biol Anim. 2014;50(5):475–81.CrossRef
266.
267.
Rastgoosalami M, et al. Evaluation of MAGE-1 cancer-testis antigen expression in invasive breast cancer and its correlation with prognostic factors. Iran J Cancer Prev. 2016;9(4):e4404.PubMedPubMedCentralCrossRef
268.
269.
Nakagawa Y, et al. Outer dense fiber 2 is a widespread centrosome scaffold component preferentially associated with mother centrioles: its identification from isolated centrosomes. Mol Biol Cell. 2001;12(6):1687–97.PubMedPubMedCentralCrossRef
270.
Shibata-Minoshima F, et al. Identification of RHOXF2 (PEPP2) as a cancer-promoting gene by expression cloning. Int J Oncol. 2012;40(1):93–8.PubMed
271.
Zou Y, Zhong W. A likely role for a novel PH-domain containing protein, PEPP2, in connecting membrane and cytoskeleton. Biocell. 2012;36(3):127–32.PubMed
272.
273.
Hsu CC, Tseng LM, Lee HC. Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood). 2016;241(12):1281–95.CrossRef
274.
275.
276.
Damm F, et al. Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia. 2012;26(2):289–95.PubMedCrossRef
277.
Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008;18(4):165–73.PubMedCrossRef
278.
Arezi P, Rezvani Z. The variation of mitochondrial NADH dehydrogenase subunit 4 (mtND4) and molecular dynamics simulation of SNPs among Iranian women with breast cancer. J Mol Graph Model. 2018;85:242–9.PubMedCrossRef
279.
Czarnecka AM, et al. Mitochondrial DNA mutations in cancer–from bench to bedside. Front Biosci (Landmark Ed). 2010;15:437–60.CrossRef
280.
Park JS, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet. 2009;18(9):1578–89.PubMedPubMedCentralCrossRef
281.
Jonckheere AI, Smeitink JA, Rodenburg RJ. Mitochondrial ATP synthase: architecture, function and pathology. J Inherit Metab Dis. 2012;35(2):211–25.PubMedCrossRef
282.
Ghaffarpour M, et al. The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients. Cancer Cell Int. 2014;14(1):21.PubMedPubMedCentralCrossRef
Metadata
Title
Genetic and molecular biology of breast cancer among Iranian patients
Author
Meysam Moghbeli
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-019-1968-2

Other articles of this Issue 1/2019

Journal of Translational Medicine 1/2019 Go to the issue

Research

Computational models for the prediction of adverse cardiovascular drug reactions

Research

Isolation of clinically relevant concentrations of bone marrow mesenchymal stem cells without centrifugation

Research

Molecular and computational analysis of 45 samples with a serologic weak D phenotype detected among 132,479 blood donors in northeast China

Research

CEBPE expression is an independent prognostic factor for acute myeloid leukemia

Review

The immunoregulation of mesenchymal stem cells plays a critical role in improving the prognosis of liver transplantation

Research

An enrichment method to increase cell-free fetal DNA fraction and significantly reduce false negatives and test failures for non-invasive prenatal screening: a feasibility study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits